This project addresses two critical needs in the canine epilepsy field, identification of effective treatments and development of validated outcome measures. Specifically, the proposed prospective, placebo-controlled, pilot clinical trial will identify associations between diet and seizures in canines and test FitBark actigraphy as a potential outcome measure to correlate seizure activity with diet.
The RCAM goals are:
1. To identify hereditary metabolic diseases within the dog and cat population,
2. To develop precise diagnostic tests for carriers and affected animals,
3. To recommend informed breeding of carrier and normal animals to preserve gene pools,
4. To maintain colonies of hereditary disorders in dogs and cats to better understand disease pathogenesis and to develop therapies, and
5. To provide tissues samples and large animal models of human genetic disease to investigators in order to better understand disease pathogenesis and as preclinical models for potential human clinical trials.
This team is focused on the interaction between cutaneous immune system and microbes. The main research of this group involves the interaction between Staphylococci and keratinocytes in canine and human atopic dermatitis.
What innovative approaches to tackle medical biofilms are needed? How can we make other stakeholders (e.g. medical care providers, engineers, veterinarians, regulatory bodies and other professionals) aware that biofilms are important?
We study the pain which arises from cancer and/or cancer treatment; our current efforts are squarely focused on:
(1) validating methods which enable robust use of companion canine/feline patients as translational models for cancer pain research, and (2) using conventional benchtop assays and rodent models, as well as innovative comparative oncology techniques, to understand the cellular and molecular underpinnings of this pain, and to understand how cancer-associated pain signaling mechanisms can be co-opted to orchestrate tumor growth and metastasis. This research will bridge the fields of neurobiology and oncology; thus, suitable candidates for the fellowship may have training in laboratory animal medicine, pathology, veterinary behavior, neurology, oncology (medical or radiation), or surgery.
This grant characterizes sensory and motor neurodevelopment in infant macaques and correlates these outcomes with brain abnormalities found on brain imaging and brain histopathology. We will identify early predictors of neurodevelopmental deficits that can be used to design future human clinical studies.
The focus of my laboratory is to improve the characterization and treatment of hereditary neurodegenerative diseases by studying naturally-occurring large animal models of human diseases. My laboratory develops and evaluates experimental therapies including gene therapy, cell-based therapy, and pharmacotherapy in canine and feline models, and develops and validates ante-mortem biochemical and magnetic resonance markers of disease severity and progression.
Inflammatory Bowel Disease (IBD) is a group of diseases that involve complex interplay between host (e.g., genetics/epigenetics), external variables (e.g., diet) and the enteric microenvironment (e.g., microbiota). Our two research labs are both interested in elucidating the host-environmental interactions that drive chronic intestinal inflammation, ultimately to improve diagnosis, therapy, and preventive steps for IBD in both dogs and humans.
This fellowship will focus on exploring the immune regulatory (IR) properties of canine regulatory T cells (Tregs) and iNKT cells in vitro and on evaluating the effects of ex vivo activated and expanded IR cells to enable successful allogeneic canine renal transplant or allogeneic off-the-shelf adoptive T cell therapies for dogs with hematological cancers.
The research focuses on understanding how lipid metabolism contributes to osteoarthritis pathophysiology. Specifically, our studies seek to determine both the therapeutic efficacy of cyclooxygenase and soluble epoxide hydrolase inhibition in osteoarthritis and understand the enzymes’ role in osteoarthritis development/progression.
Cummings School of Veterinary Medicine at Tufts University
The candidate will be able to select from projects that align with their clinical and research interests; participating laboratories are NIH funded, with a strong translational focus. Focus areas include glaucoma, in vivo electrophysiology/imaging, retinal degeneration and neuroaging.
The broad objectives of this research are to investigate recombinant lubricin and mucin therapeutics for the treatment of musculoskeletal diseases, including osteoarthritis, orthopedic infection and wound healing.
The Veterinary Microbiome Project (VMP) is aimed at creating a common repository of microbiomes from cohorts of companion animals affected by microbiome-associated conditions, including: diabetes mellitus, inflammatory bowel disease, hepatic encephalopathy, obesity, and congestive heart failure. The VMP emphasizes leveraging spontaneous large animal disease models to promote translational and comparative studies evaluating disease-associated microbiomes.
Trauma is the leading cause of death in people under the age of 45 and the third leading cause of death for people of all ages (USA), as well as the second leading cause of death in dogs (USA) and leading cause of death in cats (UK).
Understanding and defining the metabolomics of trauma patients across the translational spectrum presents opportunity to further identify clinical biochemical markers and lay the groundwork for future development of interventions for improving outcome in veterinary and human trauma patients.
Register for the site or log in to access and share research, member resources, and more.